Followed by Lyrica, original Glivec wins aagainst domestic companies over its use patent
Followed by the one of Lyrica, the use patent of ‘Glivec,’ a targeted anticancer drug, was ruled to be accepted.
Due to the ruling that dismissed the nullity trial of the use patent filed by domestic companies on GIST(gastrointestinal stromal tumor), sales of its related generic products have be...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
